What condition is indicated when a patient experiences an increase in FEV1 after a bronchodilator administration?

What condition is indicated when a patient experiences an increase in FEV1 after a bronchodilator administration?

• A. Restrictive lung disease
• B. Obstructive lung disease
• C. Mixed lung disease
• D. Reactive airway disease

Answer: (B)

An increase in Forced Expiratory Volume in one second (FEV1) after bronchodilator administration is indicative of obstructive lung disease. This response occurs because bronchodilators work to relax and open the airways, which are often narrowed or obstructed in conditions like asthma and chronic obstructive pulmonary disease (COPD). When these airways are opened, the airflow improves, leading to a measurable increase in FEV1. In obstructive lung disease, the primary issue is the difficulty in exhaling air due to the obstruction, making it difficult for patients to breathe out fully. The bronchodilator alleviates this obstruction by relaxing smooth muscle and reducing inflammation in the airways, resulting in increased airflow and higher FEV1 values. Other conditions listed, such as restrictive lung disease or mixed lung disease, would not typically show this significant improvement in FEV1 following bronchodilator therapy. Restrictive lung disease is characterized by reduced lung volume and does not usually respond to bronchodilator treatment in the same way that obstructive conditions do. Reactive airway disease could imply an asthmatic process, but it is still encompassed within the broader category of obstructive lung disease. Thus, the increase in FEV1 is most

An increase in Forced Expiratory Volume in one second (FEV1) after bronchodilator administration is indicative of obstructive lung disease. This response occurs because bronchodilators work to relax and open the airways, which are often narrowed or obstructed in conditions like asthma and chronic obstructive pulmonary disease (COPD). When these airways are opened, the airflow improves, leading to a measurable increase in FEV1.

In obstructive lung disease, the primary issue is the difficulty in exhaling air due to the obstruction, making it difficult for patients to breathe out fully. The bronchodilator alleviates this obstruction by relaxing smooth muscle and reducing inflammation in the airways, resulting in increased airflow and higher FEV1 values.

Other conditions listed, such as restrictive lung disease or mixed lung disease, would not typically show this significant improvement in FEV1 following bronchodilator therapy. Restrictive lung disease is characterized by reduced lung volume and does not usually respond to bronchodilator treatment in the same way that obstructive conditions do. Reactive airway disease could imply an asthmatic process, but it is still encompassed within the broader category of obstructive lung disease. Thus, the increase in FEV1 is most